Thursday, 15 April 2004
Friday, 16 April 2004

Organisers C.J.M. Lips (Utrecht, The Netherlands)
Th.P. Links (Groningen, The Netherlands)
Sponsors Ferring (The Netherlands)
Genzyme (The Netherlands)
Novartis Pharma BV (The Netherlands)
Novo Nordisk Pharma BV (The Netherlands)

Familial endocrine syndromes and oncological endocrinology

Session I Pheochromocytoma
Thursday morning
Chairs C.J.M. Lips (Utrecht, The Netherlands)
Th.P. Links (Groningen, The Netherlands)
Abstract number
08.30 – 09.10 Recent advances in genomics, proteomics, and localization of pheochromocytoma
K. Pacak (Bethesda, USA)
09.10 – 09.40 Pheochromocytoma: Clinical consequences and the optimal biochemical diagnostic strategy
J.W.M. Lenders (Nijmegen, The Netherlands)
09.40 – 10.05 Germline mutations in the SDHD gene and the clinical expression of paragangliomas
C.J. Cornelisse (Leiden, The Netherlands)
10.00 – 11.15 coffee break + plenary lecture
11.30 – 11.55 Genotype-phenotype correlations in phaeochromocytoma
R.R. de Krijger (Rotterdam, The Netherlands)
11.55 – 12.10 Iodine-123-Metaiodobenzylguanidine scintigraphy in localising functional paragangliomas, a pooled analysis
A.N.A. van der Horst-Schrivers, P.L. Jager, I.P. Kema, J.P. Schouten, and T.P. Links (Groningen, The Netherlands)
12.10 – 12.25 Treatment of malignant pheochromocytoma
M. Lam (Utrecht, The Netherlands)
12.25 – 12.40 Pheochromocytoma in familial syndromes
E. de Koning (Utrecht, The Netherlands)
12.40 – 13.00 discussion / end of session
13.00 – 15.00 lunch / poster viewing / exhibition + plenary lecture
Session II Carcinoid Thursday afternoon
Chairs C.J.M. Lips (Utrecht, The Netherlands)
Th.P. Links (Groningen, The Netherlands)
abstract number
15.00 – 15.30 Clinical chemistry of carcinoid tumours
I.P. Kema (Groningen, The Netherlands)
15.30 – 16.00 Diagnostic and treatment of carcinoid tumours
B. Taal (Amsterdam, The Netherlands)
16.00 – 16.30 coffee break
16.30 – 16.55 Complications of carcinoid tumours
E.G.E. de Vries / A.N.A. v.d. Horst-Schrivers (Groningen, The Netherlands)
16.55 – 17.20 Diagnosis and treatment of other neuro-endocrine tumours
W.W. de Herder (Rotterdam, The Netherlands)
17.20 – 17.35 The role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease
J.M. Zuetenhorst, C.M. Korse, J.M.G. Bonfrer, R.H. Bakker, and B.G. Taal (Amsterdam, The Netherlands)
17.35 – 17.50 Early experience of F-DOPA PET in carcinoids
P.L. Jager (Groningen, The Netherlands)
17.50 – 18.00 Carcinoid tumours in MEN 1
K. Dreyerink (Utrecht, The Netherlands)
18.00 end of session
Session III Differentiated thyroid cancer Friday morning
Chairs C.J.M. Lips (Utrecht, The Netherlands)
Th.P. Links (Groningen, The Netherlands)
Abstract number
08.30 – 9.00 Treatment of atypical epithelial thyroid carcinoma: discrepancy between iodine uptake and thyroglobulin levels
F. Pacini (Siena, Italy)
09.00 – 09.20 Novel therapies in differentiated thyroid carcinoma
J.W.A. Smit (Leiden, The Netherlands)
09.20 – 09.40 Role of nuclear medicine in differentiated thyroid carcinoma Klerk (Utrecht, The Netherlands)
09.40 – 10.05 Mutation dependent RET signaling in medullary thyroid carcinoma
R.M.W. Hofstra (Groningen, The Netherlands)
10.00 – 11.15 coffee break + plenary lecture
11.30 – 11.55 Multistep carcinogenesis in medullary thyroid carcinoma
D.S. Acton (Utrecht, The Netherlands)
11.55 – 12.15 Medullary Thyroid Carcinoma: strategies for treatment and follow-up
C.J. Lips, D.S. Acton, J.W. Höppener, G.H. Donker, E.G. Lentjes, and B.A. Zonnenberg (Utrecht, The Netherlands)
12.15 – 12.30 Inhibition of RET-mediated medullary thyroid carcinoma cell growth by imatinib
J.W.B. de Groot, I. Plaza Menacho, B.J.L. Eggen, J.Th.M. Plukker, R.M.W. Hofstra, and Th.P. Links (Groningen, The Netherlands)
12.30 – 12.45 Clinical experience with STI 571 in medullary thyroid carcinoma
B. Zonnenberg (Utrecht, The Netherlands)
12.45 – 13.00 Clinical use of rhTSH in differentiated thyroid carcinoma
Th.P. Links (Groningen, The Netherlands)
13.00 end of workshop


Intermittent androgen suppression in patients with prostate cancer
R. Kadiev (Stavropol, Russia)
Modulation of biodistribution of 131I-MIBG after Interferon and unlabeled MIBG in metastatic carcinoid
J.M. Zuetenhorst, R.A. Valdes Olmos, M. Muller, C.A. Hoefnagel, and B.G. Taal (Amsterdam, The Netherlands)